Matching articles for "Vyleesi"
Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder
The Medical Letter on Drugs and Therapeutics • July 29, 2019; (Issue 1577)
The FDA has approved bremelanotide (Vyleesi – Amag),
a melanocortin receptor agonist, for subcutaneous
treatment of premenopausal women with acquired,
generalized hypoactive sexual desire disorder...
The FDA has approved bremelanotide (Vyleesi – Amag),
a melanocortin receptor agonist, for subcutaneous
treatment of premenopausal women with acquired,
generalized hypoactive sexual desire disorder (HSDD).
Bremelanotide is not approved for use in men or
postmenopausal women. It is the second drug to
be approved in the US for this indication; flibanserin
(Addyi), which was approved in 2015, was the first.